WuXi AppTec CDMO STA Pharma inks exclusive deal with Swiss biotech BioLingus

Pills Getty
STA Pharmaceutical has signed an exclusive tech and marketing deal with Swiss biotech BioLingus for sublingual delivery of drugs. (Getty)

WuXi AppTec’s CDMO subsidiary STA Pharmaceutical has signed an exclusive tech and marketing deal with Swiss biotech BioLingus for sublingual delivery of drugs.

As part of the collaboration, WuXi STA will get exclusive access to BioLingus’ technology for sublingual and buccal delivery in the CDMO arena. The Swiss biotech’s technology centers on a platform that stabilizes and delivers sublingually—either orally or under the tongue—drug targets that include small molecules, peptides and proteins that are currently given to patients through IV.

“WuXi STA is one of the world leaders in this field, with an integrated CMC platform from preclinical development to commercialization,” Yves Decadt, chief executive for BioLingus, said in a statement. “This partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own.”

FierceBiotech Executive Breakfast

Getting Real: The Changing Tide on Real-World Evidence in Drug Development

Join FierceBiotech and a panel of industry experts for an executive breakfast at BIO. We will discuss the impacts of real-world evidence on drug development and address the important questions that companies are facing including where to find the right talent & technology and how to deploy it internally or with partners. Join us in Philadelphia on June 5th for this important discussion.

WuXi STA’s chief executive, Minzhang Chen, added that the partnership will offer more economical convenient and effective delivery solutions for patients across the globe.

Last year, the CDMO opened a new R&D center in Shanghai, right next to its production plant. WuXi STA boasts more than 1,000 scientists at five locations in China and the U.S. Globally, WuXi AppTec has more than 18,000 employees at more than two dozen facilities.

Suggested Articles

There are thousands of clinical trials ongoing around the world, but only a small percentage of patients participate. Icon is hoping to change that.

Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.

To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.